Top > Search of International Patents > GRAFT MATERIAL AND METHOD FOR PREPARING SAME

GRAFT MATERIAL AND METHOD FOR PREPARING SAME

Foreign code F180009644
File No. 4518
Posted date Nov 21, 2018
Country WIPO
International application number 2015JP064792
International publication number WO 2015178490
Date of international filing May 22, 2015
Date of international publication Nov 26, 2015
Priority data
  • P2014-107529 (May 23, 2014) JP
Title GRAFT MATERIAL AND METHOD FOR PREPARING SAME
Abstract The present invention provides a method for preparing a graft material including organ or tissue cells, wherein the method for preparing a graft material is characterized in that these cells consist of cells having inhibited PHLDA3 expression.
Outline of related art and contending technology BACKGROUND ART
As a treatment for diabetic patients, the burden on the patient's body than the pancreas transplantation is an advantage of being performed in the presence of islet transplantation.
When a maximum is an object of the pancreatic islet transplantation, the transplantation of a lower rate still possible to improve the performance but, in the current islet separation method, 100% is impossible to ensure the islet. In addition, the failure due to the islet separation, separating the pancreatic islet measuringonly ischemic state and the reason that it is exposed to the apoptosis of pancreatic islets, after separation thereof from the reduction in the number, the ability of insulin secretion is significantly reduced. Furthermore, after implantation (current methods of administering directly into the portal vein) is, the blood coagulation reaction is caused by a substance such as an inflammatory response, cells and the effect of islet itself to the implantation site in the presence of peripheral portal vein embolization is promoted by allowing the ischemia, the majority of the transplanted islets are lost at an early stage. This phenomenon, the graft material of the invention is not limited to pancreatic islets can be applied to all, to protect the graft material, to maintain the function thereof is demanded.
In order to protect the pancreatic islets EIF-5A1 can be reduced by siRNA gene expression has been proposed (Patent Document 1) is, in this method the degree of the effect was limited in duration or both.
Scope of claims (In Japanese)請求の範囲 [請求項1]
臓器もしくは組織の細胞を含む移植材料の調製方法であって、前記細胞がPHLDA3の発現抑制下の細胞から構成されることを特徴とする、移植材料の調製方法。

[請求項2]
前記移植材料が腎臓、肝臓、肺、心臓、小腸、膵臓または膵島の移植材料である、請求項1に記載の移植材料の調製方法。

[請求項3]
移植材料を構成する細胞がMEN1の機能を保持している、請求項1又は2に記載の移植材料の調製方法。

[請求項4]
移植材料の調製をPHLDA3の発現又は機能を抑制する物質の作用下に行うことを特徴とする請求項1~3のいずれかに記載の移植材料の調製方法。

[請求項5]
PHLDA3の発現抑制剤がPHLDA3のsiRNAであり、PHLDA3のsiRNAを細胞内に導入して移植材料の調製を行う、請求項4に記載の移植材料の調製方法。

[請求項6]
ジェノタイプがPHLDA3(-/-)またはPHLDA3(+/-)の細胞を用いて移植材料を調製することを特徴とする、請求項1~3のいずれかに記載の移植材料の調製方法。

[請求項7]
細胞が生体適合性のカプセルに封入されている、請求項1~6のいずれかに記載の移植材料の調製方法。

[請求項8]
臓器又は組織の細胞から構成される移植材料であって、細胞のジェノタイプがPHLDA3(-/-)またはPHLDA3(+/-)である、移植材料。

[請求項9]
非ヒト哺乳動物由来である請求項8に記載の移植材料。

[請求項10]
移植材料が膵島である、請求項8又は9に記載の移植材料。

[請求項11]
PHLDA3抑制剤を含む糖尿病治療薬。

[請求項12]
PHLDA3プロモーターの制御下にレポーター遺伝子を含む発現ベクターを導入した細胞に候補物質を作用させ、レポーター遺伝子の発現量を低下させる候補物質を選択することを特徴とする、糖尿病治療薬のスクリーニング方法。

[請求項13]
PHLDA3の発現又は機能を抑制する物質を有効成分とする移植効率向上剤。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KYOTO UNIVERSITY
  • TOHOKU UNIVERSITY
  • Inventor
  • SUMI, Shoichiro
  • SAKATA, Naoaki
  • OHKI, Rieko
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by e-mail or facsimile if you have any interests on this patent. Thanks.

PAGE TOP

close
close
close
close
close
close